The 5 arms will include patients with or without BTK C481 mutation in their CLL/small lymphocytic lymphoma (SLL) which failed a BTK inhibitor, patients with mantle cell lymphoma, marginal zone lymphoma, and Waldenstrom macroglobulinemia which failed a BTK inhibitor and an anti-CD20 monoclonal antibody therapy, patients with DLBCL which failed an anthracycline and an anti-CD20 monoclonal antibody therapy, and patients with follicular lymphoma which failed an anti-CD20 monoclonal antibody therapy. The gene discussed is BTK; the disease is marginal zone lymphoma.